Resistant Bacteria

Provid Pharmaceuticals wins SBIR grant for infectious disease program

Published in TB and Outbreaks Week, August 20th, 2002

Provid Pharmaceuticals, Inc., announced that it has been awarded an SBIR grant from the National Institute of Allergy and Infectious Diseases.

The phase I grant, in the amount of $268,000, will support the company's infectious disease research program to identify specific inhibitors of bacterial RNA polymerase, a critical enzyme responsible for gene transcription.

The project is a collaborative effort of Provid and Dr. Richard H. Ebright, Howard Hughes Medical Institute investigator and Rutgers University professor, an expert in RNA polymerase genomics and structural biology. The research plan supported by the grant is to design small molecule...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of TB and Outbreaks Week

Source: TB and Outbreaks Week (2002-08-20)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry